SlideShare una empresa de Scribd logo
Management of Women with Abnormal Pap Test
Bethesda System 2001 ,[object Object],[object Object],[object Object],[object Object]
Bethesda System 2001 ,[object Object],[object Object],[object Object],[object Object],[object Object]
Comparison of Terminology  Bethesda System CIN system Dysplasia ASCUS Cellular Atypia Unspecified Cellular  changes LSIL CIN I Mild Dysplasia HSIL CIN II Moderate dysplasia CIN III Severe Dysplasia/ CIS
Management strategy depends  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Abnormal Pap test ASCUS LSIL HSIL HPV –ve HPV +ve Rpt Pap Negative Colposcopy LEEP ECC +ve -ve Treat & Follow up Diagnostic cone Treat & Follow up
ATYPICAL SQUAMOUS CELLS
ATYPICAL SQUAMOUS CELLS ,[object Object],[object Object],[object Object],[object Object],[object Object]
ASC-US ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Recommended Management of Women with ASC-US ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Rpt Cytology @ 6 & 12 Months  HPV –ve HPV +ve Rpt Cytology @ 12 months Colposcopy  ECC if no lesions or unsatisfactory colpo  No CIN CIN Repeat Cytology  @ 6, 12 months  Or  HPV DNA test @12 months Treat & follow up ASCUS
Recommended Management  of ASC-US ,[object Object],[object Object],[object Object]
Recommended Management of Women with ASC-H  (CANNOT EXCLUDE HSIL) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
ASC-H Colposcopy ECC if no lesions  or unsatisfactory colpo CIN 2,3 > ASC or HPV+ Treat & Follow up Rpt Cytology @ 6, 12 months   OR HPV DNA Test @ 12 mths No CIN 2,3  Colposcopy Negative  Routine screening
Low Grade SIL
LSIL  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
LSIL  ,[object Object],[object Object],[object Object],[object Object],[object Object]
LSIL Colposcopy Negative Unsatisfactory colpo No lesion Satisfactory Colpo Lesion in TZ ECC No CIN CIN 2,3 Cytology @ 6, 12 mths OR HPV testing Treat & Follow up
LSIL – Post Colposcopy Management ,[object Object]
HIGH GRADE SIL HSIL
High-grade Squamous Intraepithelial Lesion (HSIL) ,[object Object],[object Object],[object Object],[object Object]
HSIL Colposcopy ECC Unsatisfactory colpo Satisfactory Colpo No CIN 2,3 Diagnostic  Excisional procedure Observe with  Cytology / Colposcopy  Treat & Follow up LEEP CIN 2,3
Managing Women with HSIL UNACCEPTABLE STRATEGIES ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
SIL in Pregnancy ,[object Object],[object Object],[object Object],[object Object],[object Object]
SIL in Pregnancy ,[object Object],[object Object],[object Object],[object Object]
ASCUS & LSIL in ADOLESCENTS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
LSIL in POSTMENOPAUSAL WOMEN ,[object Object],[object Object],[object Object],[object Object]
ATYPICAL Glandular Cells
ATYPICAL GLANDULAR CELLS  ,[object Object],[object Object],[object Object]
ATYPICAL GLANDULAR CELLS  ,[object Object],[object Object],[object Object],[object Object]
ATYPICAL GLANDULAR CELLS  ,[object Object],[object Object],[object Object],[object Object],[object Object]
AIS Hysterectomy preferred Margins involved ECC +ve Reexcision  recommended Long term  Follow up Diagnostic excisional procedure If future fertility desired Conservative Management Margins negative
Management of CIN ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
TOP 10 KEY POINTS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Más contenido relacionado

La actualidad más candente

Benign n pre malignant diseases of cx
Benign n pre malignant diseases of cxBenign n pre malignant diseases of cx
Benign n pre malignant diseases of cx
Parika Tanwar
 
Carcinoma Cervix
Carcinoma CervixCarcinoma Cervix
Carcinoma Cervix
drmcbansal
 

La actualidad más candente (20)

Cervical cancer screening modalities
Cervical cancer screening modalitiesCervical cancer screening modalities
Cervical cancer screening modalities
 
Premalignant and malignant conditions of the cervix
Premalignant and malignant conditions  of the cervix  Premalignant and malignant conditions  of the cervix
Premalignant and malignant conditions of the cervix
 
Imprint cytology
Imprint cytology Imprint cytology
Imprint cytology
 
Pap smear test
Pap smear testPap smear test
Pap smear test
 
Atlas on bethesda system for reporting cervical cytology
Atlas on bethesda system for reporting cervical cytologyAtlas on bethesda system for reporting cervical cytology
Atlas on bethesda system for reporting cervical cytology
 
Benign n pre malignant diseases of cx
Benign n pre malignant diseases of cxBenign n pre malignant diseases of cx
Benign n pre malignant diseases of cx
 
Bethesda Cervical CYtology
Bethesda Cervical CYtologyBethesda Cervical CYtology
Bethesda Cervical CYtology
 
A.B.C. of Paps Smear Update (2016) ,DR. SUDHIR JAIN Consultant Pathologist
A.B.C. of Paps Smear Update (2016) ,DR. SUDHIR JAIN  Consultant Pathologist A.B.C. of Paps Smear Update (2016) ,DR. SUDHIR JAIN  Consultant Pathologist
A.B.C. of Paps Smear Update (2016) ,DR. SUDHIR JAIN Consultant Pathologist
 
Pap smear Examination
Pap smear ExaminationPap smear Examination
Pap smear Examination
 
Interpretation of endometrial biopsy
Interpretation of endometrial biopsyInterpretation of endometrial biopsy
Interpretation of endometrial biopsy
 
Pap smear (2)
Pap smear (2)Pap smear (2)
Pap smear (2)
 
Chapter 2.4 cancer screening
Chapter 2.4 cancer screeningChapter 2.4 cancer screening
Chapter 2.4 cancer screening
 
Cancer cervix screening
Cancer cervix screeningCancer cervix screening
Cancer cervix screening
 
HPV and Cervical Cancer
HPV and Cervical CancerHPV and Cervical Cancer
HPV and Cervical Cancer
 
Carcinoma Cervix
Carcinoma CervixCarcinoma Cervix
Carcinoma Cervix
 
HPV SCREENING & CO TESTING
HPV SCREENING & CO TESTINGHPV SCREENING & CO TESTING
HPV SCREENING & CO TESTING
 
Ovarian tumors I
Ovarian tumors IOvarian tumors I
Ovarian tumors I
 
Why change to liquid based cytology
Why change to liquid based cytologyWhy change to liquid based cytology
Why change to liquid based cytology
 
Cervical intraepithelial neoplasia
Cervical intraepithelial neoplasiaCervical intraepithelial neoplasia
Cervical intraepithelial neoplasia
 
germ cell tumours of ovary
germ cell tumours of ovarygerm cell tumours of ovary
germ cell tumours of ovary
 

Similar a Abnormal Pap Test

4 prof james bently management guidelines 2014
4  prof james bently management guidelines 20144  prof james bently management guidelines 2014
4 prof james bently management guidelines 2014
Tariq Mohammed
 
fdokumen.com_lesi-pra-kanker-58e8d544505fe.ppt
fdokumen.com_lesi-pra-kanker-58e8d544505fe.pptfdokumen.com_lesi-pra-kanker-58e8d544505fe.ppt
fdokumen.com_lesi-pra-kanker-58e8d544505fe.ppt
ssuser6eec60
 
Cervical cancer screening guidelines 2013 on 7th sept
Cervical cancer screening guidelines 2013 on 7th septCervical cancer screening guidelines 2013 on 7th sept
Cervical cancer screening guidelines 2013 on 7th sept
Lifecare Centre
 

Similar a Abnormal Pap Test (20)

Cervical Cancer Screening
Cervical Cancer ScreeningCervical Cancer Screening
Cervical Cancer Screening
 
4 prof james bently management guidelines 2014
4  prof james bently management guidelines 20144  prof james bently management guidelines 2014
4 prof james bently management guidelines 2014
 
Servikal Displazi -Pap Smear - Serviks Kanseri - www.jinekolojivegebelik.com
Servikal Displazi -Pap Smear - Serviks Kanseri - www.jinekolojivegebelik.comServikal Displazi -Pap Smear - Serviks Kanseri - www.jinekolojivegebelik.com
Servikal Displazi -Pap Smear - Serviks Kanseri - www.jinekolojivegebelik.com
 
Cervical Cancer Screening
Cervical Cancer ScreeningCervical Cancer Screening
Cervical Cancer Screening
 
Cervical ca screening ..
Cervical ca screening ..Cervical ca screening ..
Cervical ca screening ..
 
Ovarian cancer .pptx
Ovarian cancer .pptxOvarian cancer .pptx
Ovarian cancer .pptx
 
Ovarian cancer .pptx
Ovarian cancer .pptxOvarian cancer .pptx
Ovarian cancer .pptx
 
LESI PRA KANKER
LESI PRA KANKERLESI PRA KANKER
LESI PRA KANKER
 
understandingtestresutsbbhvvhhgddghvgAP.ppt
understandingtestresutsbbhvvhhgddghvgAP.pptunderstandingtestresutsbbhvvhhgddghvgAP.ppt
understandingtestresutsbbhvvhhgddghvgAP.ppt
 
fdokumen.com_lesi-pra-kanker-58e8d544505fe.ppt
fdokumen.com_lesi-pra-kanker-58e8d544505fe.pptfdokumen.com_lesi-pra-kanker-58e8d544505fe.ppt
fdokumen.com_lesi-pra-kanker-58e8d544505fe.ppt
 
NHSCSP cervical screening program and treatment of CIN and CGIN
NHSCSP cervical screening program and treatment of CIN and CGINNHSCSP cervical screening program and treatment of CIN and CGIN
NHSCSP cervical screening program and treatment of CIN and CGIN
 
Lesi Pra Kanker (wecompress.com).ppt
Lesi Pra Kanker (wecompress.com).pptLesi Pra Kanker (wecompress.com).ppt
Lesi Pra Kanker (wecompress.com).ppt
 
CANCER SCREENING AND NCCP.pptx
CANCER SCREENING AND NCCP.pptxCANCER SCREENING AND NCCP.pptx
CANCER SCREENING AND NCCP.pptx
 
Management of diseases of cervix
Management of diseases of cervixManagement of diseases of cervix
Management of diseases of cervix
 
Cancer ovarian .pptx
Cancer ovarian .pptxCancer ovarian .pptx
Cancer ovarian .pptx
 
Cancer Screening
Cancer ScreeningCancer Screening
Cancer Screening
 
AUTOMOTIVE.PDF
AUTOMOTIVE.PDFAUTOMOTIVE.PDF
AUTOMOTIVE.PDF
 
Cervical Cancer Screening - HPV - www.jinekolojivegebelik.com
Cervical Cancer Screening - HPV - www.jinekolojivegebelik.comCervical Cancer Screening - HPV - www.jinekolojivegebelik.com
Cervical Cancer Screening - HPV - www.jinekolojivegebelik.com
 
Cervical cancer screening guidelines 2013 on 7th sept
Cervical cancer screening guidelines 2013 on 7th septCervical cancer screening guidelines 2013 on 7th sept
Cervical cancer screening guidelines 2013 on 7th sept
 
Breast screening
Breast screeningBreast screening
Breast screening
 

Más de drsubir

Cervical Cancer Disease Burden
Cervical Cancer Disease BurdenCervical Cancer Disease Burden
Cervical Cancer Disease Burden
drsubir
 
Colposcopy
ColposcopyColposcopy
Colposcopy
drsubir
 
Hpv Sample Collection Procedure
Hpv Sample Collection ProcedureHpv Sample Collection Procedure
Hpv Sample Collection Procedure
drsubir
 
Human Papilloma Virus
Human Papilloma VirusHuman Papilloma Virus
Human Papilloma Virus
drsubir
 
Truscreen
TruscreenTruscreen
Truscreen
drsubir
 

Más de drsubir (6)

Cervical Cancer Disease Burden
Cervical Cancer Disease BurdenCervical Cancer Disease Burden
Cervical Cancer Disease Burden
 
Colposcopy
ColposcopyColposcopy
Colposcopy
 
Hpv Sample Collection Procedure
Hpv Sample Collection ProcedureHpv Sample Collection Procedure
Hpv Sample Collection Procedure
 
Human Papilloma Virus
Human Papilloma VirusHuman Papilloma Virus
Human Papilloma Virus
 
Truscreen
TruscreenTruscreen
Truscreen
 
Via
ViaVia
Via
 

Último

Future Visions: Predictions to Guide and Time Tech Innovation, Peter Udo Diehl
Future Visions: Predictions to Guide and Time Tech Innovation, Peter Udo DiehlFuture Visions: Predictions to Guide and Time Tech Innovation, Peter Udo Diehl
Future Visions: Predictions to Guide and Time Tech Innovation, Peter Udo Diehl
Peter Udo Diehl
 

Último (20)

JMeter webinar - integration with InfluxDB and Grafana
JMeter webinar - integration with InfluxDB and GrafanaJMeter webinar - integration with InfluxDB and Grafana
JMeter webinar - integration with InfluxDB and Grafana
 
Optimizing NoSQL Performance Through Observability
Optimizing NoSQL Performance Through ObservabilityOptimizing NoSQL Performance Through Observability
Optimizing NoSQL Performance Through Observability
 
Salesforce Adoption – Metrics, Methods, and Motivation, Antone Kom
Salesforce Adoption – Metrics, Methods, and Motivation, Antone KomSalesforce Adoption – Metrics, Methods, and Motivation, Antone Kom
Salesforce Adoption – Metrics, Methods, and Motivation, Antone Kom
 
WSO2CONMay2024OpenSourceConferenceDebrief.pptx
WSO2CONMay2024OpenSourceConferenceDebrief.pptxWSO2CONMay2024OpenSourceConferenceDebrief.pptx
WSO2CONMay2024OpenSourceConferenceDebrief.pptx
 
Exploring UiPath Orchestrator API: updates and limits in 2024 🚀
Exploring UiPath Orchestrator API: updates and limits in 2024 🚀Exploring UiPath Orchestrator API: updates and limits in 2024 🚀
Exploring UiPath Orchestrator API: updates and limits in 2024 🚀
 
IOS-PENTESTING-BEGINNERS-PRACTICAL-GUIDE-.pptx
IOS-PENTESTING-BEGINNERS-PRACTICAL-GUIDE-.pptxIOS-PENTESTING-BEGINNERS-PRACTICAL-GUIDE-.pptx
IOS-PENTESTING-BEGINNERS-PRACTICAL-GUIDE-.pptx
 
Behind the Scenes From the Manager's Chair: Decoding the Secrets of Successfu...
Behind the Scenes From the Manager's Chair: Decoding the Secrets of Successfu...Behind the Scenes From the Manager's Chair: Decoding the Secrets of Successfu...
Behind the Scenes From the Manager's Chair: Decoding the Secrets of Successfu...
 
The architecture of Generative AI for enterprises.pdf
The architecture of Generative AI for enterprises.pdfThe architecture of Generative AI for enterprises.pdf
The architecture of Generative AI for enterprises.pdf
 
In-Depth Performance Testing Guide for IT Professionals
In-Depth Performance Testing Guide for IT ProfessionalsIn-Depth Performance Testing Guide for IT Professionals
In-Depth Performance Testing Guide for IT Professionals
 
Custom Approval Process: A New Perspective, Pavel Hrbacek & Anindya Halder
Custom Approval Process: A New Perspective, Pavel Hrbacek & Anindya HalderCustom Approval Process: A New Perspective, Pavel Hrbacek & Anindya Halder
Custom Approval Process: A New Perspective, Pavel Hrbacek & Anindya Halder
 
Demystifying gRPC in .Net by John Staveley
Demystifying gRPC in .Net by John StaveleyDemystifying gRPC in .Net by John Staveley
Demystifying gRPC in .Net by John Staveley
 
Free and Effective: Making Flows Publicly Accessible, Yumi Ibrahimzade
Free and Effective: Making Flows Publicly Accessible, Yumi IbrahimzadeFree and Effective: Making Flows Publicly Accessible, Yumi Ibrahimzade
Free and Effective: Making Flows Publicly Accessible, Yumi Ibrahimzade
 
Motion for AI: Creating Empathy in Technology
Motion for AI: Creating Empathy in TechnologyMotion for AI: Creating Empathy in Technology
Motion for AI: Creating Empathy in Technology
 
Speed Wins: From Kafka to APIs in Minutes
Speed Wins: From Kafka to APIs in MinutesSpeed Wins: From Kafka to APIs in Minutes
Speed Wins: From Kafka to APIs in Minutes
 
IESVE for Early Stage Design and Planning
IESVE for Early Stage Design and PlanningIESVE for Early Stage Design and Planning
IESVE for Early Stage Design and Planning
 
Connector Corner: Automate dynamic content and events by pushing a button
Connector Corner: Automate dynamic content and events by pushing a buttonConnector Corner: Automate dynamic content and events by pushing a button
Connector Corner: Automate dynamic content and events by pushing a button
 
Unpacking Value Delivery - Agile Oxford Meetup - May 2024.pptx
Unpacking Value Delivery - Agile Oxford Meetup - May 2024.pptxUnpacking Value Delivery - Agile Oxford Meetup - May 2024.pptx
Unpacking Value Delivery - Agile Oxford Meetup - May 2024.pptx
 
Future Visions: Predictions to Guide and Time Tech Innovation, Peter Udo Diehl
Future Visions: Predictions to Guide and Time Tech Innovation, Peter Udo DiehlFuture Visions: Predictions to Guide and Time Tech Innovation, Peter Udo Diehl
Future Visions: Predictions to Guide and Time Tech Innovation, Peter Udo Diehl
 
Server-Driven User Interface (SDUI) at Priceline
Server-Driven User Interface (SDUI) at PricelineServer-Driven User Interface (SDUI) at Priceline
Server-Driven User Interface (SDUI) at Priceline
 
Kubernetes & AI - Beauty and the Beast !?! @KCD Istanbul 2024
Kubernetes & AI - Beauty and the Beast !?! @KCD Istanbul 2024Kubernetes & AI - Beauty and the Beast !?! @KCD Istanbul 2024
Kubernetes & AI - Beauty and the Beast !?! @KCD Istanbul 2024
 

Abnormal Pap Test

  • 1. Management of Women with Abnormal Pap Test
  • 2.
  • 3.
  • 4. Comparison of Terminology Bethesda System CIN system Dysplasia ASCUS Cellular Atypia Unspecified Cellular changes LSIL CIN I Mild Dysplasia HSIL CIN II Moderate dysplasia CIN III Severe Dysplasia/ CIS
  • 5.
  • 6. Abnormal Pap test ASCUS LSIL HSIL HPV –ve HPV +ve Rpt Pap Negative Colposcopy LEEP ECC +ve -ve Treat & Follow up Diagnostic cone Treat & Follow up
  • 8.
  • 9.
  • 10.
  • 11. Rpt Cytology @ 6 & 12 Months HPV –ve HPV +ve Rpt Cytology @ 12 months Colposcopy ECC if no lesions or unsatisfactory colpo No CIN CIN Repeat Cytology @ 6, 12 months Or HPV DNA test @12 months Treat & follow up ASCUS
  • 12.
  • 13.
  • 14. ASC-H Colposcopy ECC if no lesions or unsatisfactory colpo CIN 2,3 > ASC or HPV+ Treat & Follow up Rpt Cytology @ 6, 12 months OR HPV DNA Test @ 12 mths No CIN 2,3 Colposcopy Negative Routine screening
  • 16.
  • 17.
  • 18. LSIL Colposcopy Negative Unsatisfactory colpo No lesion Satisfactory Colpo Lesion in TZ ECC No CIN CIN 2,3 Cytology @ 6, 12 mths OR HPV testing Treat & Follow up
  • 19.
  • 21.
  • 22. HSIL Colposcopy ECC Unsatisfactory colpo Satisfactory Colpo No CIN 2,3 Diagnostic Excisional procedure Observe with Cytology / Colposcopy Treat & Follow up LEEP CIN 2,3
  • 23.
  • 24.
  • 25.
  • 26.
  • 27.
  • 29.
  • 30.
  • 31.
  • 32. AIS Hysterectomy preferred Margins involved ECC +ve Reexcision recommended Long term Follow up Diagnostic excisional procedure If future fertility desired Conservative Management Margins negative
  • 33.
  • 34.